Novo Nordisk to Cut Thousands of Jobs Globally Amid Market Challenges

The Danish pharmaceutical giant Novo Nordisk has announced plans to eliminate approximately 9,000 jobs worldwide as part of a strategy to address declining market shares. This decision represents about 11.5% of the company's total workforce, with more than half of the positions being cut in Denmark, where the company is headquartered.

As the manufacturer known for its popular weight-loss drug Wegovy, Novo Nordisk faces increasing pressure in the competitive pharmaceutical landscape. The company has reported a significant drop in its stock value since the beginning of the year, prompting the need for this restructuring.

The restructuring process is estimated to cost the company around 8 billion Danish kroner (approximately 1.07 billion euros). However, this initial spending is anticipated to yield annual savings of the same amount starting in 2026. The goal of the reorganization is to streamline operations and expedite decision-making processes, allowing the company to focus more effectively on growth opportunities in the diabetes and obesity treatment sectors.

In light of these developments, Novo Nordisk has also revised its profit forecasts for the current year downward, further highlighting the urgency of its strategic realignment.

The company aims to create a more agile organization that can respond swiftly to market demands and enhance its competitiveness in a rapidly evolving industry.